# Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities

> **NCT04864444** · NA · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 10715 (actual)

## Conditions studied

- Malaria,Falciparum
- Malaria

## Interventions

- **DRUG:** Dihydroartemisinin-piperaquine
- **DRUG:** Primaquine

## Key facts

- **NCT ID:** NCT04864444
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-19
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-06-30
- **Target enrollment:** 10715 (ACTUAL)
- **Last updated:** 2024-06-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04864444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04864444, "Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04864444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*